{"id":"dehydrated-alcohol-injection-usp","safety":{"commonSideEffects":[{"rate":null,"effect":"Pain at injection site"},{"rate":null,"effect":"Hepatic dysfunction"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Bleeding"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dehydrated (absolute) alcohol is a sclerosing and ablative agent that works by extracting water from cells and denaturing proteins, leading to immediate coagulation necrosis and tissue destruction. When injected into pathological tissue or lesions, it creates a localized zone of cell death and fibrosis. This mechanism is used for percutaneous ablation of benign and malignant lesions, particularly in the liver and other organs.","oneSentence":"Dehydrated alcohol causes tissue ablation and coagulation necrosis through protein denaturation and cellular dehydration when injected directly into target tissue.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:08:56.264Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Percutaneous ablation of hepatocellular carcinoma"},{"name":"Ablation of benign and malignant liver lesions"}]},"trialDetails":[{"nctId":"NCT06366087","phase":"PHASE1","title":"Sublingual Atropine Bioequivalence by Route of Administration (SABER)","status":"COMPLETED","sponsor":"Biomedical Advanced Research and Development Authority","startDate":"2024-04-15","conditions":"Atropine Bioequivalence","enrollment":46},{"nctId":"NCT05324358","phase":"PHASE3","title":"Ketorolac Applied by Continuous IV Infusion for Treatment of Moderately Severe Postoperative Pain Following Bunionectomy","status":"COMPLETED","sponsor":"Neumentum, Inc.","startDate":"2022-12-14","conditions":"Pain, Postoperative","enrollment":341},{"nctId":"NCT07083765","phase":"PHASE3","title":"Renal Artery Denervation Assessment Without Antihypertensive Medication Regimen (RADAR)","status":"RECRUITING","sponsor":"Ablative Solutions, Inc.","startDate":"2025-09-01","conditions":"Hypertension, Hypertension,Essential","enrollment":142},{"nctId":"NCT04784767","phase":"PHASE1","title":"PHASE 1 SARS-COV-2-Spike-Ferritin-Nanoparticle (SpFN) Vaccine With ALFQ Adjuvant for Prevention of COVID-19","status":"COMPLETED","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2021-04-05","conditions":"SARS-CoV-2 Infection","enrollment":29},{"nctId":"NCT04233164","phase":"EARLY_PHASE1","title":"Genomic Effects of Glucocorticoids in Patients With Systemic Lupus Erythematosus","status":"COMPLETED","sponsor":"National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)","startDate":"2020-03-04","conditions":"Systemic Lupus Erythematous (SLE)","enrollment":47},{"nctId":"NCT02018250","phase":"PHASE1","title":"Study to Evaluate the Safety of a New Oxime, MMB4 DIMETHANESULFONATE (DMS)","status":"COMPLETED","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2012-03-17","conditions":"Safety and Efficacy","enrollment":32},{"nctId":"NCT02802631","phase":"PHASE1","title":"Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Minocin (Minocycline) for Injection in Healthy Adults","status":"COMPLETED","sponsor":"Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)","startDate":"2017-04-20","conditions":"Normal Healthy Volunteers","enrollment":69},{"nctId":"NCT02910414","phase":"PHASE3","title":"TARGET BP I Clinical Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ablative Solutions, Inc.","startDate":"2019-07-22","conditions":"Hypertension","enrollment":300},{"nctId":"NCT02798523","phase":"PHASE1","title":"Genomic Responses of Human Immune and Non-Immune Cells to Glucocorticoids","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-01-24","conditions":"Normal Physiology","enrollment":33},{"nctId":"NCT04290039","phase":"PHASE1","title":"Sublingual vs IV Atropine Bioavailability Study","status":"COMPLETED","sponsor":"Biomedical Advanced Research and Development Authority","startDate":"2020-01-04","conditions":"Toxic Effect of Organophosphate and Carbamate Insecticides","enrollment":15},{"nctId":"NCT04640168","phase":"PHASE3","title":"Adaptive COVID-19 Treatment Trial 4 (ACTT-4)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-12-02","conditions":"COVID-19","enrollment":1010},{"nctId":"NCT03615196","phase":"PHASE1","title":"Study of the Safety of USB005 in Healthy Volunteers","status":"COMPLETED","sponsor":"US Biotest, Inc.","startDate":"2018-07-25","conditions":"Healthy Volunteers","enrollment":32},{"nctId":"NCT01335893","phase":"PHASE1","title":"Intraoperative Imaging of Thoracic Malignancies With Indocyanine Green","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2011-05","conditions":"Lung Neoplasms","enrollment":10},{"nctId":"NCT00795678","phase":"","title":"Chemotherapeutic Agents in Brain/Breast","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2008-09","conditions":"Breast Cancer, Metastatic Cancer","enrollment":10},{"nctId":"NCT00787761","phase":"PHASE2","title":"Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer","status":"COMPLETED","sponsor":"Northside Hospital, Inc.","startDate":"2007-04","conditions":"Myeloproliferative Disorders, Kidney Cancer, Leukemia","enrollment":24}],"_emaApprovals":[],"_faersSignals":[{"count":3,"reaction":"HYPOTENSION"},{"count":2,"reaction":"ALCOHOL POISONING"},{"count":1,"reaction":"BLOOD PH DECREASED"},{"count":1,"reaction":"BRADYCARDIA"},{"count":1,"reaction":"BUNDLE BRANCH BLOCK LEFT"},{"count":1,"reaction":"BUNDLE BRANCH BLOCK RIGHT"},{"count":1,"reaction":"CARBON DIOXIDE INCREASED"},{"count":1,"reaction":"CARDIOVASCULAR DISORDER"},{"count":1,"reaction":"CEREBRAL HAEMORRHAGE"},{"count":1,"reaction":"CIRCULATORY COLLAPSE"}],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Alcohol"],"phase":"phase_3","status":"active","brandName":"Dehydrated Alcohol Injection, USP","genericName":"Dehydrated Alcohol Injection, USP","companyName":"Ablative Solutions, Inc.","companyId":"ablative-solutions-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dehydrated alcohol causes tissue ablation and coagulation necrosis through protein denaturation and cellular dehydration when injected directly into target tissue. Used for Percutaneous ablation of hepatocellular carcinoma, Ablation of benign and malignant liver lesions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}